Akero Therapeutics Profitability Analysis

AKRO Stock  USD 18.32  0.59  3.12%   
Based on Akero Therapeutics' profitability indicators, Akero Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in June. Profitability indicators assess Akero Therapeutics' ability to earn profits and add value for shareholders.
 
Net Loss  
First Reported
2017-12-31
Previous Quarter
-55.2 M
Current Value
-53.3 M
Quarterly Volatility
15.9 M
 
Covid
At this time, Akero Therapeutics' Shareholders Equity Per Share is very stable compared to the past year. As of the 26th of May 2024, Debt To Equity is likely to grow to 0.05, while PTB Ratio is likely to drop 1.49.
For Akero Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Akero Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Akero Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Akero Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Akero Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.
Is Akero Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akero Therapeutics. If investors know Akero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.24)
Return On Assets
(0.20)
Return On Equity
(0.31)
The market value of Akero Therapeutics is measured differently than its book value, which is the value of Akero that is recorded on the company's balance sheet. Investors also form their own opinion of Akero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akero Therapeutics' market value can be influenced by many factors that don't directly affect Akero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Akero Therapeutics Return On Asset vs. Return On Equity Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Akero Therapeutics's current stock value. Our valuation model uses many indicators to compare Akero Therapeutics value to that of its competitors to determine the firm's financial worth.
Akero Therapeutics is rated fourth in return on equity category among related companies. It is rated fourth in return on asset category among related companies . At this time, Akero Therapeutics' Return On Equity is very stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value Akero Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Akero Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Akero Therapeutics' earnings, one of the primary drivers of an investment's value.

Akero Return On Asset vs. Return On Equity

Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Akero Therapeutics

Return On Equity

 = 

Net Income

Total Equity

 = 
-0.31
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Akero Therapeutics

Return On Asset

 = 

Net Income

Total Assets

 = 
-0.2
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.

Akero Return On Asset Comparison

Akero Therapeutics is currently under evaluation in return on asset category among related companies.

Akero Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Akero Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Akero Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Akero Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Akero Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income270 K283.5 K
Operating Income-172.9 M-164.2 M
Net Loss-119.6 M-125.6 M
Income Before Tax-151.8 M-144.2 M
Total Other Income Expense Net21.1 M22.2 M
Net Loss-100.8 M-105.9 M
Net Loss-151.8 M-144.2 M
Income Tax Expense-2.8 M-2.7 M
Interest Income24.2 M18.1 M
Non Operating Income Net Other4.5 M4.7 M
Net Interest Income-2.6 M-2.4 M
Change To Netincome21.2 M25.8 M
Net Loss(2.89)(3.03)
Income Quality 0.96  0.61 
Net Income Per E B T 1.12  1.09 

Akero Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Akero Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Akero Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Akero Therapeutics' important profitability drivers and their relationship over time.

Akero Therapeutics Profitability Trends

Akero Therapeutics profitability trend refers to the progression of profit or loss within a business. An upward trend means that Akero Therapeutics' profit has generally increased over time, and a downward profitability trend means profits are declining. Recognizing problems early in profitability trends allows investors to address revenue and cost issues in advance. Investors and analysts usually monitor three types of profitability trends: gross, operating, and net. Gross profit is the difference between revenue and costs of goods sold. Operating profit is Akero Therapeutics' gross profit minus its overhead. After you account for other unusual revenue, expenses, and costs, you get net profit. Gross profit trends are often a good indicator of future profitability. If you have high gross profit margins, you have a better chance to cover overhead and make money.

Akero Therapeutics Profitability Drivers Correlations

One of the toughest challenges investors face today is learning how to quickly synthesize and read into endless financial statements and information provided by the company, SEC reporting, and various external parties. Understanding the correlation between Akero Therapeutics different financial indicators related to revenue and profit generation helps investors identify and prioritize their investing strategies towards Akero Therapeutics in a much-optimized way. Analyzing correlations between profit drivers that are directly associated with dollar figures is the most effective way to break down Akero Therapeutics' future profitability.

Use Akero Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Akero Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Akero Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Akero Therapeutics Pair Trading

Akero Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Akero Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Akero Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Akero Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Akero Therapeutics to buy it.
The correlation of Akero Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Akero Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Akero Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Akero Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Akero Therapeutics position

In addition to having Akero Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Small Value Funds Thematic Idea Now

Small Value Funds
Small Value Funds Theme
Funds or Etfs that invest in the undervalued stocks of small to mid-sized companies. The Small Value Funds theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Value Funds Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Akero Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Akero Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Akero Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Akero Therapeutics Stock:
Check out Trending Equities.
To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.
You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for Akero Stock analysis

When running Akero Therapeutics' price analysis, check to measure Akero Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akero Therapeutics is operating at the current time. Most of Akero Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akero Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akero Therapeutics' price. Additionally, you may evaluate how the addition of Akero Therapeutics to your portfolios can decrease your overall portfolio volatility.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
To fully project Akero Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Akero Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Akero Therapeutics' income statement, its balance sheet, and the statement of cash flows.
Potential Akero Therapeutics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Akero Therapeutics investors may work on each financial statement separately, they are all related. The changes in Akero Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Akero Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.